Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus

Paolo Bidoli, Emilio Bajetta, Simonetta C. Stani, Daniela De Candis, Armando Santoro, Maurizio Valente, Roberto Zucali, Pinuccia Valagussa, Gianni Ravasi, Gianni Bonadonna

Research output: Contribution to journalArticle

Abstract

Background. The effects of multimodality treatment on the survival of patients with esophageal carcinoma are unclear. The authors performed a prospective, Phase II study to assess the long-term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma. Methods. Of 106 consecutive patients who were recruited between 1985 and 1992, 101 patients were evaluable. Cisplatin (100 mg/m2 per day) on Day 1 and fluorouracil (1000 mg/m2 per day) on Days 1-4 were given for two cycles, with concomitant RT (30 grays [Gy] in 15 fractions) over 19 days. Patients with potentially resectable tumors were then assessed for curative surgery; the other patients received two more courses of chemotherapy and further RT (20 Gy in 10 fractions). Results. Of 40 patients who were candidates for surgery, 32 patients underwent surgery, and 24 patients had complete resection; 8 patients (25%) had no residual tumor in the specimen, and 12 patients (37%) had microscopic foci only. Surgical mortality was high (22%). Of 61 nonsurgical patients, 37 patients (61%) achieved complete clinical remission, and 14 patients (23%) achieved partial remission. The median survival for the entire series was 15 months (range, 1-136 months). The overall survival rate was 22% at 5 years and 12% at 10 years. At 10 years, freedom from disease progression was similar in the two groups (24%), whereas the median survival (22 months vs. 12 months) and the overall survival rates (17% vs. 9%) were better in nonsurgical patients compared with surgical patients, respectively, probably in relation to high surgical mortality. The larynx was preserved in 28% of 32 patients with cervical disease sites, with a 10-year disease free survival rate of 31%. Three deaths were attributed to nonsurgical treatments. Conclusions. Careful multidisciplinary pretreatment evaluation can identify patients who are ineligible for surgery without compromising long-term results. For patients with inoperable disease, chemoradiotherapy can produce relatively good long-term results. The combined approach without surgery can permit laryngeal preservation in a useful fraction of patients.

Original languageEnglish
Pages (from-to)352-361
Number of pages10
JournalCancer
Volume94
Issue number2
DOIs
Publication statusPublished - Jan 15 2002

Fingerprint

Esophagus
Squamous Cell Carcinoma
Radiotherapy
Drug Therapy
Survival
Survival Rate
Mortality
Residual Neoplasm
Chemoradiotherapy
Larynx
Fluorouracil
Cisplatin

Keywords

  • Chemoradiotherapy
  • Combined modality therapy
  • Esophageal carcinoma
  • Long-term survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bidoli, P., Bajetta, E., Stani, S. C., De Candis, D., Santoro, A., Valente, M., ... Bonadonna, G. (2002). Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. Cancer, 94(2), 352-361. https://doi.org/10.1002/cncr.10233

Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. / Bidoli, Paolo; Bajetta, Emilio; Stani, Simonetta C.; De Candis, Daniela; Santoro, Armando; Valente, Maurizio; Zucali, Roberto; Valagussa, Pinuccia; Ravasi, Gianni; Bonadonna, Gianni.

In: Cancer, Vol. 94, No. 2, 15.01.2002, p. 352-361.

Research output: Contribution to journalArticle

Bidoli, P, Bajetta, E, Stani, SC, De Candis, D, Santoro, A, Valente, M, Zucali, R, Valagussa, P, Ravasi, G & Bonadonna, G 2002, 'Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus', Cancer, vol. 94, no. 2, pp. 352-361. https://doi.org/10.1002/cncr.10233
Bidoli, Paolo ; Bajetta, Emilio ; Stani, Simonetta C. ; De Candis, Daniela ; Santoro, Armando ; Valente, Maurizio ; Zucali, Roberto ; Valagussa, Pinuccia ; Ravasi, Gianni ; Bonadonna, Gianni. / Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. In: Cancer. 2002 ; Vol. 94, No. 2. pp. 352-361.
@article{df52c885d111478fa78fd3fc2ed3846f,
title = "Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus",
abstract = "Background. The effects of multimodality treatment on the survival of patients with esophageal carcinoma are unclear. The authors performed a prospective, Phase II study to assess the long-term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma. Methods. Of 106 consecutive patients who were recruited between 1985 and 1992, 101 patients were evaluable. Cisplatin (100 mg/m2 per day) on Day 1 and fluorouracil (1000 mg/m2 per day) on Days 1-4 were given for two cycles, with concomitant RT (30 grays [Gy] in 15 fractions) over 19 days. Patients with potentially resectable tumors were then assessed for curative surgery; the other patients received two more courses of chemotherapy and further RT (20 Gy in 10 fractions). Results. Of 40 patients who were candidates for surgery, 32 patients underwent surgery, and 24 patients had complete resection; 8 patients (25{\%}) had no residual tumor in the specimen, and 12 patients (37{\%}) had microscopic foci only. Surgical mortality was high (22{\%}). Of 61 nonsurgical patients, 37 patients (61{\%}) achieved complete clinical remission, and 14 patients (23{\%}) achieved partial remission. The median survival for the entire series was 15 months (range, 1-136 months). The overall survival rate was 22{\%} at 5 years and 12{\%} at 10 years. At 10 years, freedom from disease progression was similar in the two groups (24{\%}), whereas the median survival (22 months vs. 12 months) and the overall survival rates (17{\%} vs. 9{\%}) were better in nonsurgical patients compared with surgical patients, respectively, probably in relation to high surgical mortality. The larynx was preserved in 28{\%} of 32 patients with cervical disease sites, with a 10-year disease free survival rate of 31{\%}. Three deaths were attributed to nonsurgical treatments. Conclusions. Careful multidisciplinary pretreatment evaluation can identify patients who are ineligible for surgery without compromising long-term results. For patients with inoperable disease, chemoradiotherapy can produce relatively good long-term results. The combined approach without surgery can permit laryngeal preservation in a useful fraction of patients.",
keywords = "Chemoradiotherapy, Combined modality therapy, Esophageal carcinoma, Long-term survival",
author = "Paolo Bidoli and Emilio Bajetta and Stani, {Simonetta C.} and {De Candis}, Daniela and Armando Santoro and Maurizio Valente and Roberto Zucali and Pinuccia Valagussa and Gianni Ravasi and Gianni Bonadonna",
year = "2002",
month = "1",
day = "15",
doi = "10.1002/cncr.10233",
language = "English",
volume = "94",
pages = "352--361",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus

AU - Bidoli, Paolo

AU - Bajetta, Emilio

AU - Stani, Simonetta C.

AU - De Candis, Daniela

AU - Santoro, Armando

AU - Valente, Maurizio

AU - Zucali, Roberto

AU - Valagussa, Pinuccia

AU - Ravasi, Gianni

AU - Bonadonna, Gianni

PY - 2002/1/15

Y1 - 2002/1/15

N2 - Background. The effects of multimodality treatment on the survival of patients with esophageal carcinoma are unclear. The authors performed a prospective, Phase II study to assess the long-term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma. Methods. Of 106 consecutive patients who were recruited between 1985 and 1992, 101 patients were evaluable. Cisplatin (100 mg/m2 per day) on Day 1 and fluorouracil (1000 mg/m2 per day) on Days 1-4 were given for two cycles, with concomitant RT (30 grays [Gy] in 15 fractions) over 19 days. Patients with potentially resectable tumors were then assessed for curative surgery; the other patients received two more courses of chemotherapy and further RT (20 Gy in 10 fractions). Results. Of 40 patients who were candidates for surgery, 32 patients underwent surgery, and 24 patients had complete resection; 8 patients (25%) had no residual tumor in the specimen, and 12 patients (37%) had microscopic foci only. Surgical mortality was high (22%). Of 61 nonsurgical patients, 37 patients (61%) achieved complete clinical remission, and 14 patients (23%) achieved partial remission. The median survival for the entire series was 15 months (range, 1-136 months). The overall survival rate was 22% at 5 years and 12% at 10 years. At 10 years, freedom from disease progression was similar in the two groups (24%), whereas the median survival (22 months vs. 12 months) and the overall survival rates (17% vs. 9%) were better in nonsurgical patients compared with surgical patients, respectively, probably in relation to high surgical mortality. The larynx was preserved in 28% of 32 patients with cervical disease sites, with a 10-year disease free survival rate of 31%. Three deaths were attributed to nonsurgical treatments. Conclusions. Careful multidisciplinary pretreatment evaluation can identify patients who are ineligible for surgery without compromising long-term results. For patients with inoperable disease, chemoradiotherapy can produce relatively good long-term results. The combined approach without surgery can permit laryngeal preservation in a useful fraction of patients.

AB - Background. The effects of multimodality treatment on the survival of patients with esophageal carcinoma are unclear. The authors performed a prospective, Phase II study to assess the long-term results of chemotherapy plus radiotherapy (RT) on patients with esophageal squamous cell carcinoma. Methods. Of 106 consecutive patients who were recruited between 1985 and 1992, 101 patients were evaluable. Cisplatin (100 mg/m2 per day) on Day 1 and fluorouracil (1000 mg/m2 per day) on Days 1-4 were given for two cycles, with concomitant RT (30 grays [Gy] in 15 fractions) over 19 days. Patients with potentially resectable tumors were then assessed for curative surgery; the other patients received two more courses of chemotherapy and further RT (20 Gy in 10 fractions). Results. Of 40 patients who were candidates for surgery, 32 patients underwent surgery, and 24 patients had complete resection; 8 patients (25%) had no residual tumor in the specimen, and 12 patients (37%) had microscopic foci only. Surgical mortality was high (22%). Of 61 nonsurgical patients, 37 patients (61%) achieved complete clinical remission, and 14 patients (23%) achieved partial remission. The median survival for the entire series was 15 months (range, 1-136 months). The overall survival rate was 22% at 5 years and 12% at 10 years. At 10 years, freedom from disease progression was similar in the two groups (24%), whereas the median survival (22 months vs. 12 months) and the overall survival rates (17% vs. 9%) were better in nonsurgical patients compared with surgical patients, respectively, probably in relation to high surgical mortality. The larynx was preserved in 28% of 32 patients with cervical disease sites, with a 10-year disease free survival rate of 31%. Three deaths were attributed to nonsurgical treatments. Conclusions. Careful multidisciplinary pretreatment evaluation can identify patients who are ineligible for surgery without compromising long-term results. For patients with inoperable disease, chemoradiotherapy can produce relatively good long-term results. The combined approach without surgery can permit laryngeal preservation in a useful fraction of patients.

KW - Chemoradiotherapy

KW - Combined modality therapy

KW - Esophageal carcinoma

KW - Long-term survival

UR - http://www.scopus.com/inward/record.url?scp=0037080119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037080119&partnerID=8YFLogxK

U2 - 10.1002/cncr.10233

DO - 10.1002/cncr.10233

M3 - Article

C2 - 11900221

AN - SCOPUS:0037080119

VL - 94

SP - 352

EP - 361

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -